Navigation Links
Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results
Date:2/8/2010

provided by (used in) financing activities 6,953,547 (512,505) Effect of foreign currency translation on cash 5,093 66,124 Net increase in cash and cash equivalents 7,514,350 616,188 Cash and cash equivalents - beginning 12,352,223 12,057,150 Cash and cash equivalents - ending $19,866,573 $12,673,338 Supplemental schedule of non cash activities Advance payments exchanged for intangible assets - drug $807,986 $--

Non-GAAP Financial Measures and Reconciliations

As used herein, "GAAP" refers to generally accepted accounting principals in the United States. We use various numerical measures in conference calls, investor meetings and other forums, which are or may be considered "Non-GAAP financial measures" under the SEC's Regulation G. We have provided below for your reference supplemental financial disclosure for these measures, including the most directly comparable GAAP measure and an associated reconciliation.



      Preliminary and Non-audited Second Quarter and Year to Date Fiscal 2010
                            Earnings Reconciliation

                                  Three Months  Ended      Six Months Ended
                                    December 31, 2009     December 31, 2009

    Net Income  (GAAP)                     $2,568,076            $4,756,324
    Stock Compensation Charges (a)           $900,000              $900,000
    Less: Tax Adjustment                     $163,800              $166,500
    Adjusted Net Income                    $3,304,276            $5,489,824

                                   Three Months Ended      Six Months Ended
                                    December 31, 2009     December 31, 2009

    Earnings Per S
'/>"/>
SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income
2. Tianyin Pharmaceutical Co., Inc. to Host Fiscal 2009 Earnings Conference Call on Thursday, September 24, 2009 at 10:30 a.m. ET
3. Tianyin Pharmaceutical Co., Inc. Obtains GMP Certification for Its New Production Facility
4. Tianyin Pharmaceutical, Co. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 11 at 10:50 am ET
5. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Sanqi Tablets and Yinqiao Jiedu Tablets
6. Tianyin Pharmaceutical Co., Inc. Announces Cash Dividend to Common Stockholders
7. Tianyin Pharmaceutical Co., Inc. Adopts New Sales Strategy for Azithromycin Dispersible Tablets
8. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Wednesday, February 18, 2009 at 8:45 a.m. EST
9. Tianyin Pharmaceutical Co., Inc. Implements New Sales and Marketing Strategy to Drive Revenue Growth
10. Tianyin Pharmaceutical Co., Inc. Announces First Quarter 2009 Financial Results
11. Tianyin Pharmaceutical Co., Inc. to Present at Rodman & Renshaw Annual Global Investment Conference in New York City on November 11, 2008 at 12:00 p.m. EST
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... PA (PRWEB) September 02, 2014 ... a new highly efficient, cost effective approach to ... Patent No. 8,820,265 by the U.S. Patent and ... to Opertech. , “Opertech’s taste evaluation ... the first automated high throughput system for rapid ...
(Date:9/2/2014)... Md. , Sept. 2, 2014  Synthetic ... novel anti-infective biologic and drug candidates targeting specific ... today positive results from its final preclinical toxicology ... Administration (FDA) guidance, this bridging study was required ... candidate designed to prevent the devastating effects of ...
(Date:9/2/2014)... Massachusetts , September 2, 2014 ... to BioData,s research and lab management services  ... management service, is pleased to announce the appointment of ... Culot most recently served as VP Marketing and Business ... life science research and clinical applications. Previously, ...
(Date:9/1/2014)... September 01, 2014 The Collaborative ... Diagnostics report provides comprehensive understanding and unprecedented access ... into by the worlds leading life science companies. ... analysis of how and why companies enter collaborative ... prospective partner’s negotiated deals terms provides critical insight ...
Breaking Biology Technology:Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5Louis Culot Appointed as BioData's CEO 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 3Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 4
... life sciences ... ... an,agreement to acquire Recombinant Capital, Inc. (Recap), a leading life,sciences subscription ... database that provides more than 1,500,subscribers with access to over 20 ...
... 16 Scimitar Equity, LLC issues a review ... Pipeline of Niche, Cancer Therapies with Billion Dollar ... http://www.scimitarequity.com ., VioQuest Pharmaceuticals is a ... leader in the successful development of,novel drug therapies ...
... from PAREXEL,International Corporation (Nasdaq: PRXL ), a ... than 20,sessions at the Drug Information Association (DIA) ... 22 -- 26, 2008 at the Boston Convention ... global,headquarters office. PAREXEL experts will address key industry ...
Cached Biology Technology:Deloitte Agrees to Acquire Recombinant Capital, A Leading Life Sciences Subscription Database and Advisory Services Firm 2Scimitar Equity, LLC Initiates Coverage Review of VioQuest Pharmaceuticals, Inc. 2PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting 2PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting 3PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting 4PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting 5PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting 6PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting 7
(Date:9/2/2014)... professional baseball pitchers with poor core stability are more likely ... because of injury than are pitchers who have good control ... the study, 347 pitchers were assessed for lumbopelvic control during ... they raised a leg to step up were up to ... cumulative, not consecutive during the season than were ...
(Date:9/2/2014)... to prevent Type 2 diabetes, don,t get your hopes up. ... The FASEB Journal , suggests that you don,t ... study compared genetically identical twins-one heavier and one leaner-and found ... those related to Type 2 diabetes, were found in both ... the onset of this type of diabetes is largely influenced ...
(Date:9/2/2014)... the battle between our immune systems and cholera bacteria, ... known as phages. In a new study, researchers from ... National Public Health Laboratory, and elsewhere, report that phages ... in order to survive. Importantly, the study published ... escape from phage predation occurs during human infection. , ...
Breaking Biology News(10 mins):In pro baseball pitchers, weak core linked to more missed days 2In pro baseball pitchers, weak core linked to more missed days 3What you eat and not just the number of calories, is a significant factor in diabetes risk 2War between bacteria and phages benefits humans 2War between bacteria and phages benefits humans 3
... (www.ucr.edu) -- Twenty-one undergraduate students in the UC Riverside Bourns ... researching everything from water quality to wildfires to materials that ... lot of opportunities to get involved with research," said Erika ... part in the Summer Bridge program. "This is the reason ...
... Tampa, Fla. (July 26, 2010) Australian ... "reprogrammed" adult mouse fat cells and neural cells to ... of different cells (pluripotency). The cells, called "induced pluripotent ... occurring pluripotent stems cells, such as embryonic stem cells, ...
... which a herpes virus invades cells has remained a mystery ... University of Pennsylvania reveals the unusual structure of a key ... to invade cells. The new map details an essential ... a new target for antiviral drugs. The research was ...
Cached Biology News:Undergrad engineers research everything from water quality to wildfires this summer 2Scientists 'reprogram' mouse fat cells into clinically useful stem cells 2A collaboration solves the herpes virus protein structure providing new drug therapy directions 2A collaboration solves the herpes virus protein structure providing new drug therapy directions 3